Preliminary results of a first-in-human phase 1b (aCCeleR8-001) study of S-531011, a humanized anti-CCR8 monoclonal antibody, in patients with advanced solid tumors.

Authors: Toshihiko Doi, Taroh Satoh, Noboru Yamamoto, Clara Hwang, Omid Hamid, Anthony J. Olszanski, Feng Zeng, Takayuki Katsube, Michael Jon Chisamore, Tomohiko Harada

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.3076

Source: Full article


Abstract

3076